trial impact

About Us



Vishal Jajodia is the Chief Innovator and CEO of Swati Spentose Pvt. Ltd., a 100 % subsidiary of the 39 years old Euresian Group. He has single handedly established an enviable API manufacturing business with forward integration into development of new salts and therapeutic applications, including preclinical studies in prestigious globally acclaimed institutes like Mt Sinnai School of Medicine, New York.

Vishal Jajodia has been an active player in the pharmaceutical industry for over 16 years. Since he took over the family business of manufacturing API in 1992, he has expanded the second-generation family business from selling into 15 countries to over 54 countries at present. He has transformed his company profile from being a small API manufacturer to an innovative research driven company in last ten years. He is proud to launch three new molecules for the world markets, out of which one of them is a NCE launched for the first time in the global platform, in collaboration with worldwide renowned scientists from Australia, Europe and America. His path breaking global scientific collaborations in areas of polysaccharides and exemplary initiatives in the areas of neglected disease of interstitial cystitis are commendable.

He has been an active player for over fourteen years in various export promotion councils like Chemexcil, Pharmexcil and FIEO under Ministry of Commerce, Government of India and has also successfully lead campaigns and delegations to resolve complicated EXIM policy issues for the exporters.

Vishal Jajodia is also associated with industry bodies such as the Chemical Export Promotion Council, Ministry of Commerce, the Pharma Export Promotion Council, Ministry of Commerce; the Export Tax Grievances forum ? Federation of Indian Exporters, Ministry of Commerce, Government of India and is the Elected Board Member of Indian Drug Manufacturers Association (IDMA).

In addition to opening complicated markets like South America, where he was one of the first two Indian corporate to establish themselves in 1994, Mr. Vishal Jajodia has two key leadership qualities ? his ability to resolve complex situations with simple and viable business solutions, and his ability to get high performers to work in a team.

Vishal believes that any success can be designed on sound and intelligent financial practices. With this in mind, his fully forward and backward integrated business structures are sure to generate sustainable revenues to bring new health solutions to market.



Swati Spentose Pvt Ltd is a 100 % subsidiary of the 39 years old Euresian Group, which has presence in more than 54 countries.

It aims to bring valuable research of scientists to market. SSPL has formulated unique cutting edge strategies to being new health care solution for those suffering using complex carbohydrate chemistry.

The key therapeutic areas of Swati Spentose include Urology, Nephrology, Inflammation and pain management.

The mission of Swati Spentose is to provide quality contract manufacturing services and be a platform for multinationals companies in Europe, US and Asia who look up to India as the fastest emerging economy in the world.

Euresian group is one of the oldest companies in India in contract manufacturing and advance drug research space. The group was founded in 1970 has come a long way by making its presence felt in healthcare and advance research field and aims to bring change in the world with its cutting-edge technology and research driven practices. They have invested Rs 50 crore in a globally enviable business platform of manufacturing and research at Vapi to achieve the above ambitious initiatives in areas of neglected disease like interstitial cystitis and orphan molecules like pentosan. SSPL has delivered their promise of leading the global initiative on interstitial cystitis by formation of the IC Congress out of Europe with worlds leading though leaders and KOL?s.